Myovant Sciences to Host Fiscal Second Quarter 2022 Earnings Conference Call at 5:00 p.m. EST on October 26, 2022

0

[ad_1]

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), today announced that it will host a webcast and conference call to discuss company updates and financial results for its fiscal second quarter, ended September 30, 2022. The webcast and the conference call will take place at 5:00 p.m. Eastern Time. / 2:00 p.m. PT on October 26, 2022.

Investors and the general public can access the live webcast here. The live webcast can also be accessed by visiting the Company’s Investor Relations page on Myovant’s website at: https://investors.myovant.com/.

The webcast will be archived on the company’s website for approximately one year.

ABOUT MYOVANT SCIENCES
Myovant Sciences aspires to redefine care for women and men through goal-oriented science, empowering medicines and transformative advocacy. Founded in 2016, Myovant has completed five Phase 3 clinical trials in oncology and women’s health, leading to three U.S. Food and Drug Administration (FDA) regulatory approvals for men with a advanced prostate cancer, women with heavy menstrual bleeding associated with uterine fibroids, and premenopausal women with moderate to severe pain associated with endometriosis, respectively. Myovant has also received regulatory approvals from the European Commission (EC) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with breast cancer. advanced hormone-responsive prostate. Myovant has an additional New Drug Application under review with the FDA for United States Prescribing Information (USPI) updates based on safety and efficacy data from the withdrawal study Phase 3 LIBERTY (RWS) trial of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids for up to two years. Myovant is also conducting a phase 3 study to assess pregnancy prevention in women with uterine fibroids or endometriosis. In addition, Myovant is developing MVT-602, an investigational kisspeptin-1 oligopeptide receptor agonist, which has completed a Phase 2a study in female infertility in assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is the majority shareholder of Myovant. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor contacts:
Uneek Mehra
Financial and Commercial Director
Myovant Sciences, Inc.

[email protected]

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.

[email protected]


main logo

[ad_2]
Source link

Share.

Comments are closed.